Sweden
· Delayed Price · Currency is SEK Xspray Pharma AB Statistics
Total Valuation
Xspray Pharma AB has a market cap or net worth of SEK 1.55 billion. The enterprise value is 1.51 billion.
| Market Cap | 1.55B |
| Enterprise Value | 1.51B |
Important Dates
The last earnings date was Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Xspray Pharma AB has 33.76 million shares outstanding. The number of shares has increased by 36.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 33.76M |
| Shares Change (YoY) | +36.35% |
| Shares Change (QoQ) | +3.12% |
| Owned by Insiders (%) | 6.84% |
| Owned by Institutions (%) | 38.65% |
| Float | 22.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.64 |
| P/TBV Ratio | 2.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.83 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.51 |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.90 |
| Quick Ratio | 1.46 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.17 |
| Interest Coverage | -9,632.71 |
Financial Efficiency
Return on equity (ROE) is -41.42% and return on invested capital (ROIC) is -22.57%.
| Return on Equity (ROE) | -41.42% |
| Return on Assets (ROA) | -21.08% |
| Return on Capital (ROIC) | -22.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -10.75M |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.97% in the last 52 weeks. The beta is 0.92, so Xspray Pharma AB's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | +1.97% |
| 50-Day Moving Average | 49.71 |
| 200-Day Moving Average | 53.97 |
| Relative Strength Index (RSI) | 49.17 |
| Average Volume (20 Days) | 32,492 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -231.19M |
| Pretax Income | -258.19M |
| Net Income | -258.05M |
| EBITDA | -224.55M |
| EBIT | -231.19M |
| Earnings Per Share (EPS) | -7.90 |
Balance Sheet
The company has 74.76 million in cash and 33.61 million in debt, giving a net cash position of 41.15 million or 1.22 per share.
| Cash & Cash Equivalents | 74.76M |
| Total Debt | 33.61M |
| Net Cash | 41.15M |
| Net Cash Per Share | 1.22 |
| Equity (Book Value) | 585.59M |
| Book Value Per Share | 17.34 |
| Working Capital | 47.96M |
Cash Flow
In the last 12 months, operating cash flow was -193.39 million and capital expenditures -6.99 million, giving a free cash flow of -200.39 million.
| Operating Cash Flow | -193.39M |
| Capital Expenditures | -6.99M |
| Free Cash Flow | -200.39M |
| FCF Per Share | -5.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Xspray Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.35% |
| Shareholder Yield | -36.35% |
| Earnings Yield | -17.26% |
| FCF Yield | -12.96% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |